Dryness & GSM faq

Do I need to stop blood thinners before procedures?

Not always. Many dryness/GSM appointments are low-risk and can be done while you continue anticoagulants (e.g., apixaban, rivaroxaban, warfarin) or antiplatelets (aspirin, clopidogrel), especially for non-invasive care. For procedures with a bleeding risk (e.g., some injectables), the plan is individual and balances clot risk and bleed risk with your prescriber. Never stop a blood thinner without medical advice. Educational only. Results vary. Not a cure.

Clinical Context

Who may not need to stop? Most people attending for assessment, advice, moisturiser/lubricant selection, local oestrogen/DHEA, or carefully selected energy-based treatments. For GSM-related dryness, the foundation steps (moisturiser + suitable lubricant) are entirely compatible with anticoagulants and antiplatelets.

Who needs an individual plan? Anyone on warfarin with variable INR; people on dual antiplatelet therapy after a recent stent; those with very high clot risk (mechanical valve, recent VTE); or those with a history of bleeding issues. For superficial injectables, we usually continue medicines but optimise timing, pressure and aftercare; decisions are made with your prescriber.

Next steps. Never stop blood thinners on your own. Share your medicine list, recent INR (if on warfarin), kidney function (for DOACs), and any previous procedure-bleeding history. We’ll map symptoms, choose low-friction options (e.g., silicone-based lubricants, gentle cleansing), and agree a plan that keeps you safe while addressing vaginal dryness/atrophy and dyspareunia.

Evidence-Based Approaches

NHS overview: General information on anticoagulants and warfarin explains uses and bleeding risks, helpful when planning even minor procedures.

NICE/BNF guidance: The NICE Menopause Guideline (NG23) covers first-line GSM care (moisturisers, lubricants, and low-dose local vaginal oestrogen). Drug-specific cautions and dosing for anticoagulants and local vaginal therapies are set out in the British National Formulary (BNF).

Regulator context (UK): Safety and vigilance principles for devices/procedures are outlined by the UK regulator; see the MHRA medical devices pages.

Peer-reviewed evidence: Reviews of peri-procedural management of direct oral anticoagulants and warfarin (public abstracts via PubMed) describe risk stratification, timing around doses, and why many low-bleeding-risk interventions proceed without interruption.

Applying the evidence: Use a stepped GSM plan aligned with NICE (moisturiser/lubricant → consider local oestrogen/DHEA) and, for procedures with bleed potential, make an individual plan rather than stopping medicines by default. Good placement (e.g., at the vestibule), meticulous technique, and friction-minimising aftercare reduce bleeding and improve comfort.